5 results about "Membrane associated" patented technology

This invention discloses lysosome-targeting chimeras based on different ratios and molecular weights, their preparation methods, and applications, belonging to the field of biomedical technology. Lysosome-targeting chimera (LYTAC) molecules contain target protein ligands, linkers, and lysosome-targeting receptor ligands. The core of this invention lies in systematically regulating the molecular weight ratio (range 1:1 to 1:10) between the target protein ligand and the lysosome-targeting receptor ligand, as well as the total molecular weight of LYTAC (range 1000 Da to 5000 Da), to obtain a series of LYTAC molecules with different properties. This invention provides a method for preparing the LYTAC molecules via chemical coupling. Experiments show that by optimizing the above parameters, the LYTAC molecules prepared by this invention can significantly improve the degradation efficiency and specificity of extracellular and membrane-associated target proteins (such as PD-L1, EGFR, etc.), while optimizing their pharmacokinetic properties, showing broad application prospects in the treatment of cancer, neurodegenerative diseases, and other fields.

A method for treating a cancer in a subject, the method comprising administering a therapeutically effective amount of a membrane- associated tyrosine and threonine-specific cdc2-inhibatory kinase (Myt1) inhibitor, wherein the cancer comprises a truncating biallelic loss- of-function mutation in FBXW7 is disclosed. In a preferred embodiment, the Myt1 inhibitor is a compound of Formula (I). TheMyt1 inhibitors may bee used in combination with other therapeutic agents. Such agents include Wee 1l inhibitor, Fen 1 inhibitor, Top 1 inhibitor, Rrm1 inhibitor, Rrm2 inhibitor, Aurkb inhibitor, Top2A inhibitor, ATR inhibitor, Ttk inhibitor, Sod 1 inhibitor, Sod2 inhibitor, Bub 1 inhibitor, Cdc7 inhibitor, Sae 1 inhibitor, Plk1 inhibitor, Uba2 inhibitor, Out inhibitor, Hdac3 inhibitor, Chek1 inhibitor, Aurka inhibitor, Men 1 inhibitor, Dot 1 I inhibitor, Crebbp inhibitor, Ezh2 inhibitor, Plk4 inhibitor, Haspin inhibitor, Mettl3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof.